Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Viatris (VTRS)
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-11-04
$18.97-1.30%
Close 2026-11-05 · 1-day change
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
2.68 → 2.71 EPS · FY ending Dec 31, 2027 · 7 analysts
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 5, 2026 to Nov 4, 2026: (new ÷ prior − 1). Contributor count changed from 7 to 7; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for VTRS yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Enterprise-wide cost review improves efficiency | A supporting condition in Viatris's published investment case. The stated target is Sustain cost savings from strategic review in 2026. | Intact | Cost savings do not materialize or reverse in 2026 | Qualitative condition This condition has no defined numerical measure. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 4 of 8 supplied quarters. Management reported: “In addition, management believes the potential savings related to these committed restructuring activities will be between $600 million and $700 million once fully implemented, with most of these savings expected to improve operating cash flow.” ““Commercial execution, pipeline progress and the early benefits of our enterprise-wide strategic review continue strengthening our business and improving our financial performance.” Operating income was $6.300 million in 2026-Q2. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a restructuring and execution story, with recent financial performance strong and the sector backdrop supportive. The long-term thesis remains intact, but the evidence is mixed: earnings quality is loss-making and management execution is described as volatile.
The valuation evidence describes VTRS as cheap versus peers, while the expectations gap is negative, suggesting expectations are not demanding. The priced-in assessment is tagged as justified, with low fragility and medium model confidence.
Near term, recent results and guidance revisions point to continued execution: management raised 2026 guidance, and restructuring remains on track toward annual cost savings. Product launches are progressing, though that priority is on watch; the company also has a 23% estimated miss probability and a history of a deep miss.
Over the next few quarters, the thesis depends on management sustaining the recently raised guidance and delivering the planned cost savings. A guidance reversal would damage credibility, while continued progress at sector peers could support the broader Healthcare backdrop; weakening jobs data is a risk.
For a 1-to-3-year view, VTRS has improving execution and cost discipline, but the thesis still depends on reliable delivery amid loss-making earnings quality and volatile management signals. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Free cash flow reaches about $2.15B in 2026 | Free cash flow should reach $2.15B. | Intact | Free cash flow falls below $2.0B in FY26 | Free cash flow: $329M FY2026-Q2; GAAP. Published target: ~$2.15B. Annual target cannot be compared with a quarterly or TTM observation. Aug 6, 2026329,000,000 USD · calculatedLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
New product revenue grows toward $450M-$550M in 2026 | A supporting condition in Viatris's published investment case. The stated target is Deliver $450M to $550M new product revenue in 2026. | Intact | New product revenue fails to grow beyond $71M in Q1 run rate | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Revenue reaches about $14.7B in 2026 | A primary condition in Viatris's published investment case. The stated target is ~$14.7B. | Intact | Revenue falls below $13.9B in FY26 | Revenue: $3.757B FY2026-Q2; GAAP. Published target: ~$14.7B. Annual target cannot be compared with a quarterly or TTM observation. Aug 6, 20263,756,800,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$2.63 → $2.71 · observed estimates
$15.05B → $15.25B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $2.63 | $15,051,413,720 | 9 / 7 |
| 2026-07-25 | $2.63 | $15,051,413,720 | 9 / 7 |
| 2026-07-26 | $2.63 | $15,051,413,720 | 9 / 7 |
| 2026-07-27 | $2.63 | $15,051,413,720 | 9 / 7 |
| 2026-07-28 | $2.63 | $15,051,413,720 | 9 / 7 |
| 2026-07-29 | $2.63 | $15,053,886,191 | 5 / 6 |
| 2026-07-30 | $2.63 | $15,040,027,240 | 9 / 7 |
| 2026-07-31 | $2.63 | $15,053,886,191 | 5 / 6 |
| 2026-08-01 | $2.63 | $15,053,886,191 | 5 / 6 |
| 2026-08-02 | $2.63 | $15,053,886,191 | 5 / 6 |
| 2026-08-03 | $2.63 | $15,053,886,191 | 5 / 6 |
| 2026-08-04 | $2.63 | $15,040,027,240 | 9 / 7 |
| 2026-08-05 | $2.63 | $15,053,886,191 | 5 / 6 |
| 2026-08-06 | $2.63 | $15,040,027,240 | 9 / 7 |
| 2026-08-08 | $2.63 | $15,053,886,191 | 5 / 6 |
| 2026-08-09 | $2.66 | $15,047,488,110 | 9 / 7 |
| 2026-08-10 | $2.66 | $15,047,488,110 | 9 / 7 |
| 2026-08-12 | $2.63 | $15,053,886,191 | 5 / 6 |
| 2026-08-13 | $2.66 | $15,028,550,010 | 9 / 7 |
| 2026-08-14 | $2.63 | $15,053,886,191 | 5 / 6 |
| 2026-08-15 | $2.63 | $15,053,886,191 | 5 / 6 |
| 2026-08-16 | $2.63 | $15,053,886,191 | 5 / 6 |
| 2026-08-17 | $2.63 | $15,053,886,191 | 5 / 6 |
| 2026-08-18 | $2.63 | $15,053,886,191 | 5 / 6 |
| 2026-08-19 | $2.63 | $15,053,886,191 | 5 / 6 |
| 2026-08-20 | $2.68 | $15,032,433,846 | 5 / 6 |
| 2026-08-21 | $2.68 | $15,032,433,846 | 5 / 6 |
| 2026-08-22 | $2.68 | $15,032,433,846 | 5 / 6 |
| 2026-08-23 | $2.68 | $15,032,433,846 | 5 / 6 |
| 2026-08-24 | $2.68 | $15,032,433,846 | 5 / 6 |
| 2026-08-25 | $2.68 | $15,032,433,846 | 5 / 6 |
| 2026-08-26 | $2.68 | $15,032,433,846 | 5 / 6 |
| 2026-08-27 | $2.68 | $15,032,433,846 | 5 / 6 |
| 2026-08-28 | $2.68 | $15,032,433,846 | 5 / 6 |
| 2026-08-29 | $2.68 | $15,032,433,846 | 5 / 6 |
| 2026-08-30 | $2.68 | $15,032,433,846 | 5 / 6 |
| 2026-08-31 | $2.68 | $15,032,433,846 | 5 / 6 |
| 2026-09-01 | $2.68 | $15,032,433,846 | 5 / 6 |
| 2026-09-02 | $2.68 | $15,032,433,846 | 5 / 6 |
| 2026-09-03 | $2.68 | $15,032,433,846 | 5 / 6 |
| 2026-09-04 | $2.68 | $15,032,433,846 | 5 / 6 |
| 2026-09-05 | $2.66 | $15,032,433,846 | 5 / 6 |
| 2026-09-06 | $2.66 | $15,032,433,846 | 5 / 6 |
| 2026-09-07 | $2.66 | $15,032,433,846 | 5 / 6 |
| 2026-09-08 | $2.66 | $15,032,433,846 | 5 / 6 |
| 2026-09-09 | $2.66 | $15,032,433,846 | 5 / 6 |
| 2026-09-10 | $2.67 | $15,066,671,868 | 5 / 6 |
| 2026-09-11 | $2.67 | $15,066,671,868 | 6 / 6 |
| 2026-09-12 | $2.67 | $15,066,671,868 | 6 / 6 |
| 2026-09-13 | $2.67 | $15,066,671,868 | 6 / 6 |
| 2026-09-14 | $2.67 | $15,066,671,868 | 6 / 6 |
| 2026-09-15 | $2.67 | $15,066,671,868 | 6 / 6 |
| 2026-09-16 | $2.67 | $15,066,671,868 | 6 / 6 |
| 2026-09-17 | $2.67 | $15,059,171,868 | 6 / 6 |
| 2026-09-18 | $2.67 | $15,059,171,868 | 6 / 6 |
| 2026-09-19 | $2.67 | $15,059,171,868 | 6 / 6 |
| 2026-09-20 | $2.67 | $15,059,171,868 | 6 / 6 |
| 2026-09-21 | $2.67 | $15,059,171,868 | 6 / 6 |
| 2026-09-22 | $2.67 | $15,059,171,868 | 6 / 6 |
| 2026-09-23 | $2.67 | $15,059,171,868 | 6 / 6 |
| 2026-09-24 | $2.67 | $15,059,171,868 | 6 / 6 |
| 2026-09-25 | $2.68 | $15,041,150,385 | 7 / 7 |
| 2026-09-26 | $2.68 | $15,041,150,385 | 7 / 7 |
| 2026-09-27 | $2.68 | $15,041,150,385 | 7 / 7 |
| 2026-09-28 | $2.68 | $15,041,150,385 | 7 / 7 |
| 2026-09-29 | $2.68 | $15,041,150,385 | 7 / 7 |
| 2026-09-30 | $2.68 | $15,041,150,385 | 7 / 7 |
| 2026-10-01 | $2.68 | $15,041,150,385 | 7 / 7 |
| 2026-10-02 | $2.68 | $15,041,150,385 | 7 / 7 |
| 2026-10-03 | $2.68 | $15,041,150,385 | 7 / 7 |
| 2026-10-04 | $2.68 | $15,041,150,385 | 7 / 7 |
| 2026-10-05 | $2.68 | $15,041,150,385 | 7 / 7 |
| 2026-10-06 | $2.68 | $15,041,150,385 | 7 / 7 |
| 2026-10-07 | $2.68 | $15,041,150,385 | 7 / 7 |
| 2026-10-08 | $2.68 | $15,041,150,385 | 7 / 7 |
| 2026-10-09 | $2.68 | $15,041,238,747 | 7 / 7 |
| 2026-10-10 | $2.68 | $15,041,238,747 | 7 / 7 |
| 2026-10-11 | $2.68 | $15,044,457,497 | 7 / 7 |
| 2026-10-12 | $2.68 | $15,044,457,497 | 7 / 7 |
| 2026-10-13 | $2.68 | $15,044,457,497 | 7 / 7 |
| 2026-10-14 | $2.68 | $15,044,457,497 | 7 / 7 |
| 2026-10-15 | $2.68 | $15,044,457,497 | 7 / 7 |
| 2026-10-16 | $2.69 | $15,044,457,497 | 7 / 7 |
| 2026-10-17 | $2.69 | $15,044,457,497 | 7 / 7 |
| 2026-10-18 | $2.69 | $15,044,457,497 | 7 / 7 |
| 2026-10-19 | $2.69 | $15,044,457,497 | 7 / 7 |
| 2026-10-20 | $2.69 | $15,044,457,497 | 7 / 7 |
| 2026-10-21 | $2.69 | $15,044,457,497 | 7 / 7 |
| 2026-10-22 | $2.71 | $15,151,906,635 | 7 / 7 |
| 2026-10-23 | $2.71 | $15,151,906,635 | 7 / 7 |
| 2026-10-24 | $2.71 | $15,151,906,635 | 7 / 7 |
| 2026-10-25 | $2.71 | $15,151,906,635 | 7 / 7 |
| 2026-10-26 | $2.71 | $15,151,906,635 | 7 / 7 |
| 2026-10-27 | $2.71 | $15,151,906,635 | 7 / 7 |
| 2026-10-28 | $2.72 | $15,250,119,135 | 7 / 7 |
| 2026-10-29 | $2.72 | $15,250,119,135 | 7 / 7 |
| 2026-10-30 | $2.72 | $15,250,119,135 | 7 / 7 |
| 2026-10-31 | $2.71 | $15,247,961,010 | 7 / 7 |
| 2026-11-01 | $2.71 | $15,247,961,010 | 7 / 7 |
| 2026-11-02 | $2.71 | $15,247,961,010 | 7 / 7 |
| 2026-11-03 | $2.71 | $15,247,961,010 | 7 / 7 |
| 2026-11-04 | $2.71 | $15,247,961,010 | 7 / 7 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 7 Buy / Strong Buy · 4 Hold · 1 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 2 recorded
0 raises · 0 cuts · 0 unchanged · 1 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Nov 5, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.